Next Generation News and Research

RSS

Caliper to acquire CRi for $20.0 million

Caliper Life Sciences, Inc., a leading provider of products and services for drug discovery research, today announced that it has entered into a definitive agreement to acquire privately-held Cambridge Research & Instrumentation, Inc. (CRi) for approximately $20.0 million, including net debt. CRi's patented preclinical and tissue-based multiplexed analysis systems will expand Caliper's life sciences tools portfolio, particularly as it bridges into clinical research, pathology and clinical market applications.

10 Dec 2010

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that a Phase 3 pivotal study with OncoVEXGM-CSF for the first line treatment of patients with locally advanced squamous cell carcinoma of the head & neck has commenced.

10 Dec 2010

Ingenuity Systems and CLC bio collaborate to provide interoperability between software solutions

Today Ingenuity Systems and CLC bio announced that they're collaborating to provide interoperability between their software solutions. The aim of the partnership is to provide researchers with the ability to easily exchange data between CLC bio's enterprise and desktop solutions and Ingenuity's pathway analysis software (IPA®), in order to perform both array and next-generation sequencing data and knowledge analyses.

9 Dec 2010

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

9 Dec 2010

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.

9 Dec 2010

Vaccine World Summit to be held in New Delhi 1-3 March, 2011

From the 1st to the 3rd of March 2011, vaccine leaders from developing and developed world will meet at Vaccine World Summit in New Delhi. The event will be hosted by IMAPAC, in partnership with DCVMN (Developing Countries Vaccine Manufacturers Network).

8 Dec 2010

St. Luke's Episcopal Hospital, UH College of Pharmacy earn national 'best practices' award

With antibiotic resistance on the rise worldwide, health care professionals are continually seeking to optimize how they combat drug-resistant infections.

8 Dec 2010

ART's stent superior than other bioresorbable stents

Arterial Remodeling Technologies disclosed today new data related to its bioresorbable stent platform—additional data that further validates the Company's innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption within a bioresorbable PLA (polylactic acid) stent.

8 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

$Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma$

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

7 Dec 2010

CSC's Leading Edge Forum: Disruptive technologies to reshape delivery of healthcare

CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.

7 Dec 2010

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Acetylon Pharmaceuticals today announced the publication of favorable results of preclinical safety and efficacy testing of its oral selective HDAC6 inhibitor drug candidate, ACY-1215, in multiple myeloma.

7 Dec 2010

Research reveals new standard treatment options for various forms of lymphoma

The next generation of drug therapies and enhanced treatment approaches for various forms of lymphoma are evolving as researchers continue to better understand how these cancers progress. Research will be presented today at the 52nd Annual Meeting of the American Society of Hematology introducing promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable (referring to patients with clinical stage I or II disease and one or more risk factors) Hodgkin disease.

6 Dec 2010

Event reporting prevents medication errors in primary care: Study

The most frequent contributors to medication errors and adverse drug events in busy primary care practice offices are communication problems and lack of knowledge, according to a study of a prototype web-based medication error and adverse drug event reporting system.

4 Dec 2010

BMEYE signs licensing agreement with PULSION Medical Systems

BMEYE's Breakthrough Totally Noninvasive Blood Pressure and Cardiac Output Technology Will be Incorporated Into PULSION's Next Generation Patient Monitors

3 Dec 2010

New approach to biomarker detection for early lung cancer diagnosis

Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.

2 Dec 2010

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.

2 Dec 2010

Argonne researchers awarded 65 million hours of computing time on Blue Gene/P supercomputer

Four researchers at the U.S. Department of Energy's (DOE) Argonne National Laboratory lead projects that have been awarded a total of 65 million hours of computing time on Argonne's energy-efficient Blue Gene/P ("Intrepid") supercomputer. The researchers will conduct advanced simulation and analysis, performing virtual experiments that would be almost impossible and impractical in the natural world. They will also develop scalable system software needed to fully harness the power of supercomputers.

2 Dec 2010

CSL Behring launches next generation HeliTrax System for Apple's devices

CSL Behring announced today the availability of the next generation HeliTrax System as part of a specially designed software platform for Apple's iPhone, iPod touch, or iPad devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring's recombinant factor VIII (rFVIII).

2 Dec 2010

'Margaret Foti Award' for best thesis in translational oncology established

The American Association for Cancer Research, in cooperation with the University of Catania Ph.D. Oncology Program and the Italian League Against Cancer of Catania, announces the establishment of the "Margaret Foti Award" for the best thesis in translational oncology. The first awards will be given on Dec. 2, 2010, in Catania, Italy.

1 Dec 2010